Published in Exp Neurol on October 01, 1999
Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A (2003) 2.27
Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A (2003) 2.14
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Differentiation of human embryonic stem cells to regional specific neural precursors in chemically defined medium conditions. PLoS One (2008) 1.36
Requirement of the orphan nuclear receptor SF-1 in terminal differentiation of ventromedial hypothalamic neurons. Mol Cell Neurosci (2003) 1.21
Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev (2003) 1.13
Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci (2008) 1.10
Dopamine systems in the forebrain. Adv Exp Med Biol (2009) 1.00
Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. Br J Pharmacol (2011) 0.94
Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult. Neuroscience (2007) 0.92
Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci (2004) 0.90
The aetiology of idiopathic Parkinson's disease. Mol Pathol (2001) 0.88
Sall3 is required for the terminal maturation of olfactory glomerular interneurons. J Comp Neurol (2008) 0.88
Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease. Neurobiol Aging (2011) 0.85
Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner. Stem Cells (2015) 0.82
Nurr1 regulates Top IIβ and functions in axon genesis of mesencephalic dopaminergic neurons. Mol Neurodegener (2012) 0.82
Nurr1-Based Therapies for Parkinson's Disease. CNS Neurosci Ther (2016) 0.80
Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. Chin Med J (Engl) (2015) 0.78
Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(-/-) mice. Neurobiol Aging (2015) 0.77
Enhancing Beta-Catenin Activity via GSK3beta Inhibition Protects PC12 Cells against Rotenone Toxicity through Nurr1 Induction. PLoS One (2016) 0.76
Genetic and neuroendocrine regulation of the postpartum brain. Front Neuroendocrinol (2016) 0.75
Nuclear receptors in neural stem/progenitor cell homeostasis. Cell Mol Life Sci (2017) 0.75
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell (1991) 7.93
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev (1995) 7.16
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature (1998) 6.29
An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science (2001) 6.07
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 5.79
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
Structure of the bacteriophage phi29 DNA packaging motor. Nature (2000) 5.25
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
A putative exchange factor for Rho1 GTPase is required for initiation of cytokinesis in Drosophila. Genes Dev (1999) 3.25
Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain (1995) 2.99
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol (1989) 2.91
Essential tremor: clinical correlates in 350 patients. Neurology (1991) 2.89
Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med (1992) 2.86
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A (1998) 2.76
Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology (2005) 2.72
Mortality attributable to cigarette smoking in China. JAMA (1997) 2.72
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science (1974) 2.69
The morbidity and mortality of vermiculite miners and millers exposed to tremolite-actinolite: Part I. Exposure estimates. Am J Ind Med (1987) 2.66
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 2.57
Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology (2000) 2.48
Psychogenic myoclonus. Neurology (1993) 2.39
Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 2.38
The impact of depressive symptoms in early Parkinson disease. Neurology (2007) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Synthesis of epothilones A and B in solid and solution phase. Nature (1997) 2.35
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med (1999) 2.33
Dopaminergic and ligand-independent activation of steroid hormone receptors. Science (1991) 2.33
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology (2004) 2.26
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol (1995) 2.21
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg (1997) 2.15
Mental-physical co-morbidity and its relationship with disability: results from the World Mental Health Surveys. Psychol Med (2008) 2.15
High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J Clin Microbiol (2009) 2.13
A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod (1998) 2.12
Depression-anxiety relationships with chronic physical conditions: results from the World Mental Health Surveys. J Affect Disord (2007) 2.12
Identification of a new brain-specific transcription factor, NURR1. Mol Endocrinol (1992) 2.11
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 2.10
Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. J Biol Chem (1997) 2.06
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A (1999) 2.03
Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 2.01
Delayed-onset progressive movement disorders after static brain lesions. Neurology (1996) 1.96
Transcriptional repression by the proto-oncogene BCL-6. Oncogene (1996) 1.94
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Quantitative specificity of the Mnt repressor. J Mol Biol (1997) 1.91
Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science (2013) 1.91
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Hemifacial spasm: clinical findings and treatment. Muscle Nerve (1998) 1.88
Occupational exposure to bisphenol-A (BPA) and the risk of self-reported male sexual dysfunction. Hum Reprod (2009) 1.87
Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol (1983) 1.87
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Deficiency in fatty acid synthase leads to premature cell death and dramatic alterations in plant morphology. Plant Cell (2000) 1.84
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Dopamine activation of an orphan of the steroid receptor superfamily. Science (1991) 1.78
A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol (1981) 1.75
Structure determination of the head-tail connector of bacteriophage phi29. Acta Crystallogr D Biol Crystallogr (2001) 1.74
Extrapyramidal involvement in Rett's syndrome. Neurology (1990) 1.74
Detection of incidental colorectal tumours with 18F-labelled 2-fluoro-2-deoxyglucose positron emission tomography/computed tomography scans: results of a prospective study. Colorectal Dis (2011) 1.73
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 1.68
Quantum criticality and nodal superconductivity in the FeAs-based superconductor KFe2As2. Phys Rev Lett (2010) 1.68
Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience (2009) 1.67
P-element mutations affecting embryonic peripheral nervous system development in Drosophila melanogaster. Genetics (1995) 1.65
The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology (1985) 1.65
A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology (2005) 1.63
Field performance of transgenic elite commercial hybrid rice expressing bacillus thuringiensis delta-endotoxin. Nat Biotechnol (2000) 1.62
The alien hand and related signs. J Neurol Neurosurg Psychiatry (1992) 1.62
P-element insertion alleles of essential genes on the third chromosome of Drosophila melanogaster: mutations affecting embryonic PNS development. Genetics (1997) 1.60
Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron (1996) 1.58
Orthostatic tremor: an association with essential tremor. Mov Disord (1991) 1.58
Intrathecal baclofen for intractable axial dystonia. Neurology (1991) 1.58
atonal regulates neurite arborization but does not act as a proneural gene in the Drosophila brain. Neuron (2000) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
CooA, a CO-sensing transcription factor from Rhodospirillum rubrum, is a CO-binding heme protein. Proc Natl Acad Sci U S A (1997) 1.57
Tardive oculogyric crises. Neurology (1989) 1.56
From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc Natl Acad Sci U S A (1997) 1.56
Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol (1986) 1.56
Intrarenal production of angiotensin II. Semin Nephrol (1997) 1.55
Reproductive phenotpes of the progesterone receptor null mutant mouse. J Steroid Biochem Mol Biol (1996) 1.55
Pallidotomy for generalized dystonia. Mov Disord (1998) 1.54
Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. Eur J Neurol (2009) 1.54
Characterization of the region encoding the CO-induced hydrogenase of Rhodospirillum rubrum. J Bacteriol (1996) 1.54
Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem (2001) 1.54
Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg (1988) 1.53
Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry (1985) 1.52
Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med (1975) 1.52
Syntaxin 1A interacts with multiple exocytic proteins to regulate neurotransmitter release in vivo. Neuron (1999) 1.52
Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci (2001) 1.52
Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology (2001) 1.52
Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol (1993) 1.51
Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci (2004) 1.50
The complete genome of Enterovirus 71 China strain. Sci China C Life Sci (2001) 1.50
Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Ann Neurol (1994) 1.50